Stefaniak, Aleksandra A.
Pereira, Manuel P.
Zeidler, Claudia
Ständer, Sonja
Article History
Accepted: 5 December 2021
First Online: 21 February 2022
Declarations
:
: No sources of funding were used to conduct this study or prepare this manuscript.
: AAS has no conflicts of interest that are directly relevant to the content of this article. MPP has served as an investigator for Trevi Therapeutics, is a consultant for Galderma, and has received speaker honoraria/travel fees from AbbVie, Beiersdorf, Eli Lilly, Galderma, Menlo Therapeutics, Novartis, P. G. Unna Academy, and Trevi Therapeutics. CZ has served as an investigator in clinical trials for Novartis, Janssen, Pfizer, UCB, Lilly, AbbVie, Boehringer Ingelheim, Sanofi, Regeneron, Leo, and Galderma; has received speaker honoraria from Dermasence, Beiersdorf, and Leo; and has received author honoraria from AbbVie. SS has served as an investigator in clinical trials for Dermasence, Galderma, Kiniksa, Menlo Therapeutics, Novartis, Sanofi, Trevi Therapeutics, and Vanda Therapeutics and as a consultant and/or member of an advisory board for AbbVie, Almirall, Beiersdorf, Bellus, Bionorica, Cara Therapeutics, Celgene, Clexio, DS Biopharma, Escient, Galderma, Leo, Lilly, Kiniksa, Menlo, Novartis, Pfizer, Sanofi, Trevi Therapeutics, and Vifor.
: Not applicable.
: Consent was obtained for publication of patient photographs included in this manuscript.
: Not applicable.
: Not applicable.
: All authors contributed significantly to the concept and planning, drafting, and revision of the manuscript. All authors approved the final submitted version of the manuscript.